Markets:

Overview

News

Currencies

International

Treasuries

Aclaris Therapeutics, Inc. - Common Stock (NQ:ACRS)

4.430 +1.810 (+69.08%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aclaris Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday ↗

September 14, 2023

A bull on the company became more positive on its prospects.

Via The Motley Fool

Smartsheet, Kroger, Lantronix And Other Big Stocks Moving Higher On Friday ↗

September 08, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session. Lantronix, Inc. (NASDAQ: LTRX) shares jumped 26.3% to...

Via Benzinga

Topics Stocks

PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday ↗

August 29, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Insiders Buying Freshpet And 2 Other Stocks ↗

August 29, 2023

Although U.S. stocks closed higher on Monday, there were a few notable insider trades.

Via Benzinga

Aclaris Therapeutics Earnings Perspective: Return On Capital Employed ↗

May 22, 2023

Via Benzinga

Aclaris Therapeutics's Earnings Outlook ↗

May 05, 2023

Via Benzinga

(ACRS) - Analyzing Aclaris Therapeutics's Short Interest ↗

March 08, 2023

Via Benzinga

Analyst Ratings for Aclaris Therapeutics ↗

March 07, 2023

Via Benzinga

2 Low-Priced Stocks That Could Make You Richer ↗

June 26, 2023

These two low-priced healthcare stocks could skyrocket within the next 12 months.

Via The Motley Fool

Why Aclaris Therapeutics Topped the Market on Tuesday ↗

June 13, 2023

Investors were cheered by the latest laboratory news from the company.

Via The Motley Fool

3 Biotech Stocks to Sell Before They’re 6 Feet Under ↗

April 24, 2023

Biotech stocks with no earnings, no cash, and no path to profit will have no chance at survival. Here's three such biotech stocks to avoid.

Via InvestorPlace

Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason ↗

March 07, 2023

Via Benzinga

Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday ↗

March 07, 2023

U.S. stocks traded lower, with the Dow Jones dropping around 150 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Why Aclaris Therapeutics Is Crashing Today ↗

March 06, 2023

The company announced disappointing results from a phase 2a clinical study.

Via The Motley Fool

Why Aclaris Therapeutics Stock Is Plunging Today ↗

March 06, 2023

Via Benzinga

Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 07, 2023

Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the...

Via Benzinga

DocuSign To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

March 07, 2023

Wells Fargo cut the price target for Cheniere Energy, Inc. (NYSE: LNG) from $236 to $230. Wells Fargo analyst Michael Blum maintained an Overweight rating. Cheniere Energy shares fell 4.8% to close at...

Via Benzinga

Aclaris Therapeutics's Return On Capital Employed Insights ↗

February 27, 2023

Via Benzinga

Looking Into Aclaris Therapeutics's Return On Capital Employed ↗

December 05, 2022

Via Benzinga

These 2 Biotech Stocks Made Big Monday Moves ↗

March 06, 2023

Find out which was the winner and which was the loser.

Via The Motley Fool

Nasdaq Rises 50 Points; Ciena Earnings Top Expectations ↗

March 06, 2023

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Monday. The Dow traded up 0.16% to 33,444.91 while the NASDAQ rose 0.43% to 11,739.11. The S&P...

Via Benzinga

As Focus Shifts From Hidradenitis Suppurativa, Analyst Seems Bullish On Aclaris ↗

March 06, 2023

Aclaris Therapeutics Inc (NASDAQ: ACRS) flunked a 12-week, Phase 2a study of zunsemetinib (ATI-450) for moderate to severe hidradenitis suppurativa.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

March 06, 2023

On Monday, 36 companies set new 52-week lows.

Via Benzinga

Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 06, 2023

Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 06, 2023

Via Benzinga

Dow Jumps Over 100 Points; BridgeBio Pharma Shares Spike Higher ↗

March 06, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Monday. The Dow traded up 0.42% to 33,531.77 while the NASDAQ rose 0.97% to 11,802.73. The S&P 500...

Via Benzinga

Nasdaq Rises 50 Points; US Factory Orders Down 1.6% In January ↗

March 06, 2023

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 33,471.14 while the NASDAQ rose...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 06, 2023

Via Benzinga

Week In Review: Full-Life Acquires Focus-X And Its Eight Radiotherapeutics In $245 Million Deal ↗

December 04, 2022

Full-Life Technologies, a Brussels-Shanghai radiotherapeutics company, will acquire Focus-X Therapeutics for up to $245 million. Using its proprietary peptide engineering technology, Focus-X has built...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 ↗

December 14, 2022

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.